Targeting RNA Congress 2021
2021-03-15 - 2021-03-17 | Virtual Summit EST Timezone
Targeting RNA is set to be the next big thing; 85% of human genome transcribed to RNA but only 3% translated into proteins, therefore making it an obvious target. With Risdiplam being approved by the FDA in August, and several major collaborations also being penned throughout 2020, including a $190 million deal between Arrakis and Roche, it seems like a good time to target these protein precursors.

The Targeting RNA Congress will return for 2021, March 15-17, and will take a look at the latest techniques to analyse and predict protein structure, as well as hearing from leading researchers and industry on how to incorporate learnings from RNA biology into potent and selective ligands to help prevent, rather than treat, disease.
Key Outcomes from the summit include:

Learn where to target your RNA molecules after exploring the newest biophysical techniques to analyse RNA structure, including NMR, Cryo-EM, and in silico modelling with Silvi Rouskin, (MIT), Wah Chiu (Stanford University) and Hashim Al Hashimi (Duke University).
Understand what makes a druggable RNA target and hear from expert RNA biologists to advise how best to drug your favourite RNA targets with Anima Biotech and Craig Blain (Arrakis).
Get translational insights into what considerations are important when creating a small molecule that targets RNA by learning how to develop tools for assessment of RNA targets with Amanda Garner (University of Michigan)
Hear what new techniques can help to drug these tricky targets, including RNAi, RNA degraders and RIBOTACs with Gene Yeo (UCSD), Jonathan Hall (Zurich) and Matt Disney (Scripps and Expansion).

To know more about Targeting RNA Congress please click here.

SMi’s 2nd Annual AI in Drug Discovery
2021-03-15 - 2021-03-16 | Online Access Only
Chaired by: Darren Green, Director of Molecular Design & Senior Fellow, GSK
Sponsored by: OpenEye Scientific Software
Exploring the latest Innovations in Machine Learning for Enhancing Discovery Pipelines
SMi is proud to present its 2nd Annual AI in Drug Discovery Conference, taking place on the 15-16 March 2021.
With the global Artificial Intelligence (AI) in Drug Discovery Market size expected to exceed $3,900 million by 2027, the conference agenda will encompass key drivers leading the way into a shorter, cheaper, and more successful R&D era. The conference will be a particular focus on case studies from leading pharma and biotech, as well as a close-up view on the paradigm shift from undruggable targets to ‘challenging to drug’.

Furthermore the event will focus on 4 key themes: machine learning and automation for improved drug discovery pipelines; effective prediction of compound properties; data robustness and curation; innovative use of AI for rare and undruggable diseases, and will highlight key case studies across these themes, uncovering key developments in pharma of data optimization and to aid therapeutic discovery. Real-world examples of AI in structure-based drug design and patient relevant data will be explored in eye-opening detail
Event Hashtag: #SMiAIDrugDis
HIGHLIGHTS FOR 2021 INCLUDE:

Discover the latest innovations in AI-based drug discovery platforms
Engage in case study presentations from leading pharma and biotech companies on machine learning and improved drug discovery pipelines
Understand how AI can be effectively implemented to enhance productivity
Delve into best practices in data quality, curation, and validation
Explore how AI is being used to unlock therapies that have evaded traditional drug discovery

KEY SPEAKERS INCLUDE

Noor Shaker, CEO, Glamorous AI
Maria Luisa Pineda, Co-Founder & CEO, Envisagenics
Ed Addison, Co-founder, Chairman, and CEO, Cloud Pharmaceuticals
Liling Warren, Director, Head of Translational Medicine Statistics, Teva Pharmaceuticals
Lili Peng, Associate Director Scientific Ecosystem Analytics Lead, Biogen
Mark De Pristo, CEO, BigHat Biosciences
Philipe Moingeon, Head of Immuno-inflammation, Servier
Hugo Ceulemans, Scientific Director, Discovery Data Sciences, Janssen
Peter Henstock, Machine Learning & AI Lead, Pfizer
Naheed Kurji, CEO, Cyclica

WHO SHOULD ATTEND
CEOs, Presidents, Vice Presidents and Global Heads, Executive Directors, Vice President & Global head, Principal Scientists, Heads of Business Development, Directors of Pharma/Biotech firms.

Parallel Trade 2021 – Virtual conference: online access only
2021-03-22 - 2021-03-23 | Virtual Event
Exploring the challenges, practices and drivers in the aftermath of the transition for Parallel Trade
SMi present’s its 15th annual Parallel Trade virtual conference, taking place virtually on the 22nd and the 23rd March 2021. As the only parallel trade conference in Europe, this event provides the perfect platform for industry experts from both sides of the coin to come together and share perspectives on the practice of parallel trade.

The 2021 event will be more significant than ever before due to the transition period after Brexit coming to an end this year. As such, the UK will no longer be part of the EU free market. This will mean increased medicines prices, reduced access to some specialist drugs and greater risk of supply chain shortages. In a post-Brexit environment, exhaustion of rights will cease to apply to the UK, making import and export a costly business and in a worst-case scenario could effectively kill parallel distribution.
This conference will bring together industry experts to discuss the challenges and drivers of the industry, including the EU regulatory landscape and the impact of the FMD (Falsified Medicines Directive). The conference will also provide global insights on Parallel trade and will reflect on key takeaways for other member states.
Register online for only £999: www.parallel-trade.com/pjwl
The benefits of attending:
Learn new perspectives and case studies through presentation, panel discussions and interactive workshops from industry KOLs. Engage in a platform discussion inclusive of all different facets of parallel trade in analysing the overall state of the market. Explore the effects and impact of the Falsified Medicines Directive and how to best comply to these practices. Collaborate and share ideas of how a hard Brexit will impact the EU market and affect parallel trade practices. Discover what the industry has learnt from COVID-19 and the impact on export bans.
Plus, one post-conference interactive workshop
Workshop: The law of parallel trade: past, present and future
Workshop Leaders:
Christopher Stothers, Partner, Bruckhaus Freshfields Deringer
Sharon Malhi, Senior Associate, Antitrust, Competition and Trade, Bruckhaus Freshfields Deringer
Who should attend:
Vice President/ Heads of/General Managers:

International Trade and Relations
Supply Chain Development – Brexit
Brexit Implementation
Market Access
Supply Chain Manager
Parallel trade reporting
Regulatory Affairs
IP
Purchasing
Policy Patent Operations
European Affairs
Supply and Demand
Attorney
Distribution

Additional Contact Info:
T: +44 (0)20 7827 6088
E: hsidhu@smi-online.co.uk
LinkedIn: @SMi Pharma
Twitter: @SMiPharm #SMi #SMiParallel

FcRn-Targeted Therapies for Autoimmune Disorders Summit
2021-03-23 - 2021-03-25 | Virtual Event
The neonatal Fc receptor (FcRn) plays a fundamental role in the transcytosis, half-life extension, and recycling of human serum albumin and IgG, however in the case of more than 100+ rare and autoimmune disorders, this can not only be detrimental, but lethal to the health of the individual. Following the high profile J&J-Momenta deal, UCB’s rozanolixizumab expects a Ph3 readout in H1 2021 and Argenx’s efgartigimod awaits US filing by the end of 2020, other large players are poised to bring their candidates through the clinic in rapid succession.

The digital FcRn-Targeted Therapies for Autoimmune Disorders Summit is not only the first, but the only dedicated meeting that brings you the most up to date clinical and commercial developments utilizing FcRn antagonists in rare and autoimmune diseases.
The 3-day program will bring together a wealth of knowledge into the complexities of the FcRn-IgG interaction and the therapeutic strategies which are being employed to yield clinical efficacy. Expect to hear from industry leaders showcasing clinical candidates aimed at disrupting the autoantibody interaction and increasing the clearance of pathogenic IgG from the body.
Join 100+ experts online from companies such as CSL Behring, Eli Lilly, Roche, Momenta, Alexion, Argenx and more to discuss FcRn MOA, preclinical model selection and translation, high throughput assays for ligand screening, IgG engineering, and DMPK modelling to ensure best in class medicines are brought to patients. Including an exclusive workshop lead by the FDA who will be exploring protein immunogenicity to better understand FcRn drug development.

5th Annual MarketsandMarkets High Potent Medicines Virtual Conference (CET TIME ZONE)
2021-03-23 - 2021-03-24 | Virtual
One of the major challenges faced by the players in this market, especially CMOs that offer HPAPI manufacturing services, is the continual evolution of industry standards, technologies, and regulations.
Owing to their target release characteristics, HPAPIs find major applications in target therapies for cancer. Globally, there is a significant growth in the incidence of cancer. Diseases like musculoskeletal diseases, glaucoma, and specifically cancer have a significant impact on the health status of people worldwide, with comparatively higher growth rates in developing countries.
The 5th Annual MarketsandMarkets High Potent Medicines Virtual Conference to be held on 23-24 March 2021. This conference would address the challenges in continual evolution of industry standards, technologies, and regulations. Leading experts from the industry will discuss the strategies for both in-house manufacturing and outsourcing by presenting expert keynote presentations, live case studies and breakthrough panel discussions.
Event Website https://events.marketsandmarkets.com/5th-annual-marketsandmarkets-high-potent-medicines-virtual-conference/
Registration link: https://events.marketsandmarkets.com/5th-annual-marketsandmarkets-high-potent-medicines-virtual-conference/register

Cytokine-Based Cancer Immunotherapies Summit
2021-03-24 - 2021-03-25 | Digital Event
Pioneering Research to Develop Safe & Effective Immunomodulators to Stimulate the Soluble Tumor Microenvironment
The renewed interest in the anti-tumor properties of cytokines has led to an increase in the number of clinical trials that explore the safety and efficacy of cytokine-based drugs, not only as single agents, but also in combination with other immunomodulatory drugs.

Therapeutically targeting of soluble immune modulators in the tumor microenvironment (TME) has been shown to create a ‘hot’ tumor, increasing T cell infiltration and improving response rates to immune checkpoint blockade treatment. The immuno-oncology research community is pivoting towards engineering soluble factors and cytokines to transform the TME into an immunostimulatory state, acting as a complementary strategy to a suite of cancer immunotherapies approaches.
The virtual Cytokine-Based Cancer Immunotherapies Summit has been established to give drug developers insight into the latest clinical advancements and stimulate discussions around how to take immuno-oncology combinations forward to meet the vast unmet need of cancer patients.
Join us and leading experts from Roche, CytomX, Philogen, Bristol-Myers Squibb, Novartis and many more to discuss how to reduce toxicity and achieve an efficacious dose, determining the mechanisms of action and hear the latest data coming out of the clinic.
To know more about Cytokine-Based Cancer Immunotherapies Summit please click here.

Animal Microbiome Congress
2021-03-24 - 2021-03-25 | Virtual
The 4th Annual Animal Microbiome Congress taking place on the 24-25th March 2021 will provide the latest clinical data and facilitate interactions between academia and industry to accelerate the commercialization of animal microbiome research. This global market is forecast to grow to 9.7 billion by 2028 due to demand for innovation from the rapidly growing meat, aquaculture, and pet healthcare industries to meet an increasing need to replace antibiotics and satisfy the world’s growing hunger for protein. Over 4 years and 7 events, we have built an international animal microbiome community of 600+ people from 30+ countries.

Through comprehensive industry-academic discussion panels, engaging keynotes, interactive roundtables, and virtual networking this congress will enable participants to be at the forefront of modulating the animal microbiome to meet commercial goals, sustainably and safely. Our goal is to support smart interactions between business and academia to enable participants to capitalize on the growing global animal microbiome market. Due to this year’s virtual format, we have advanced our networking capabilities to help you recreate the unexpected interactions that drive the future of your work. We have incorporated: network roulette enabling 30 + chance encounters, Deep Dive Roundtable groups of 9 people working together to tackle industry issues, interactive content delivery to facilitate discussion and pre-arranged meetings to broaden your network strategically.
Join us and discover the critical breakthroughs on: uncovering the full functional potential of the microbiome in aquaculture, production, and companion animals, improving health outcomes for production and companion animals, reducing the cost of animal ownership and making farming more sustainable, and translating academic research into commercial products whilst steering through challenging regulatory hurdles.
Book now to join us in unlocking the full functional potential of the Animal Microbiome.

8th Edition MarketsandMarkets Biomarker and Companion Diagnostics Virtual Conference ( Time Zone - CENTRAL EUROPEAN TIME (CET)
2021-03-24 - 2021-03-26 | Virtual
The 8th Edition Biomarker and Companion Diagnostics Virtual Conference scheduled to be held on 25 – 26 March 2021 would address the gaps between early stage biomarker development and the commercialization stage of biomarkers. This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers, Precision Medicine and Big Data.
Regarding commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to clinical translation of biomarkers.
Event Website https://events.marketsandmarkets.com/8th-edition-marketsandmarkets-biomarker-and-companion-diagnostics-virtual-conference/
Registration link: https://events.marketsandmarkets.com/8th-edition-marketsandmarkets-biomarker-and-companion-diagnostics-virtual-conference/register

5th Annual MarketsandMarkets Infection Control, Sterilization & Decontamination Virtual Conference (GMT)
2021-03-25 - 2021-03-26 | Virtual
Based on the survey on 1,000 hospitals in 33 countries, European Centre for Disease Prevention and Control (ECDC) estimates that that on any given day, one in 18 patients in a European hospital has healthcare-associated infection (HAIs). Most the countries (26 out of 33) reported the major three types of HAIs: pneumonia and lower respiratory tract infection, surgical site infection and urinary tract infection.
The estimated number of patients in UK acquiring HAIs is approx. 300,000 a year, according to a report by National Institute for Health and Care Excellence (NICE). It costs the NHS approximately £1 billion a year, and £56 million of this is estimated to be incurred after patients are discharged from hospital. NHS has now adopted no-tolerance policy towards spread of HAIs.
MarketsandMarkets is organizing 5th Annual Infection Control, Sterilization and Decontamination in Healthcare Virtual Conference, scheduled for 25th & 26th March 2021, aiming at providing platform to experts from hospitals, academia, and government institutions discussing the innovations, challenges, and future aspects of infection control, decontamination, and sterilization.
Event Website: https://events.marketsandmarkets.com/5th-annual-marketsandmarkets-infection-control-sterilization-decontamination-virtual-conference/
Registration link: https://events.marketsandmarkets.com/5th-annual-marketsandmarkets-infection-control-sterilization-decontamination-virtual-conference/register

LEAP HR: Life Sciences Spring Edition
2021-03-29 - 2021-03-31 | Exclusive Virtual Conference
LEAP HR: Life Sciences Spring Edition is your best opportunity to uncover the radical strategies biopharma people leaders are putting in place to ensure they are a flexible employer of choice in a competitive industry.
This unique forum is shining a light on how the boldest life sciences HR leaders are rethinking the HR function and redefining the workforce of the future in order to continue to innovate and thrive in the face of change.
Step inside the HR innovation that is making a difference to employees, patients and customers – and leave with a brand new playbook for the people function to thrive in a post-vaccine world.
To know more about LEAP HR: Life Sciences Spring Edition please click here.

Gene Therapy Comparability
2021-03-30 - 2021-04-01 | Digital Event
The inaugural Gene Therapy Comparability Summit is the only industry dedicated meeting to ensuring your manufacturing processes are effective and comparable at every stage of development, supporting a seamless transition to the larger scales required for commercialization.
This meeting will unite large pharma and innovative biotechs including Pfizer, Biogen, BioMarin and Takeda as they share best practices, lessons learned and analytical data across the comparability lifecycle.

Focused specifically on enhancing your gene therapy comparability approach, join us to ensure you maintain safety, quality, consistency and efficacy throughout scale-up from clinical to commercial-scale manufacturing, and satisfy regulatory demands to avoid costly delays to clinical programs.
Incorporating insights from leading CMC, Regulatory, Analytical and Process Development experts, this is your opportunity to gain extensive technical information on challenges like ensuring manufacturing processes are comparable when changing facilities and cell lines, developing effective bioassays for use in comparability studies and handling the limited gene therapy lots available.
Join your peers online and discover:

How Biogen defined a robust comparability strategy for late phase gene therapy products
Gain insights into the planning and considerations for a comparability study and risk assessment and understand what defines process comparability vs analytical comparability with Amicus Therapeutics
Hear from the National Institute of Biology and discover if results of non-related analytical methods can be directly compared
Learn from the Italian Medical Agency and take a deep dive into regulatory expectations for ATMP comparability and comparability exercises
Explore next generation sequencing (NGS) and how its application can be utilized for comprehensive rAAV genome characterization with Biogen
Better understand the challenges associated with limited batch retention and sample availability in the context of comparability and learn best practices for mitigating such challenges with Gyroscope Therapeutics

View the full event guide to find out more!

Pharma: Clinical 2021
2021-04-07 - 2021-04-09 | Virtual Event
Reuters Events’ Clinical 2021 (April 7-9) is the new home of clinical collaboration, innovation and discovery. Join hundreds of pharma clinical innovators plus leaders from across the business, such as real-world evidence, medical, and patient centricity, alongside key regulatory bodies, providers, and patient representatives to form new collaborations and gain new insights through presentations, case-studies, workshops and collaborative working groups.
To know more about Pharma: Clinical 2021 please click here.

MarketsandMarkets qPCR and dPCR Virtual Conference
2021-04-15 - 2021-04-16 | Virtual Event
Advancing qPCR and dPCR technological developments and its applications in oncology and infectious disease diagnostics
As per MarketsandMarkets research analysis, the global dPCR and qPCR is estimated to grow to USD 6,270.9 million by 2024 at a CAGR of 8.8%. Factors such as the rising incidences of target infectious diseases and genetic disorders; continuous technological advancements in PCR technologies; increasing investments, funds, and grants; increasing use of biomarker profiling for disease diagnostics; and successful completion of the Human Genome Project are driving the growth of this market. However, the high instrument costs—especially that of dPCR—and the technical limitations of PCR have restricted their greater use

MarketsandMarkets are proud to host its inaugural “qPCR and dPCR Virtual Conference” which will be held on 15th – 16th April 2021. The conference will focus on the latest developments in digital and real time PCR and also, its application in cancer diagnosis and infectious disease diagnostics
Event Website: https://events.marketsandmarkets.com/marketsandmarkets-qpcr-and-dpcr-virtual-conference/
Registration link: https://events.marketsandmarkets.com/marketsandmarkets-qpcr-and-dpcr-virtual-conference/

AI Driven Drug Repositioning and Repurposing Summit
2021-04-20 - 2021-04-21 | Virtual Event
The AI Driven Drug Repositioning & Repurposing Summit will bring together 80+ leaders in repurposing and pioneers in AI and machine learning to strategize how repurposing can reach its full potential to:

Improve time and cost savings of drug development
Leverage the safety advantage in reducing development risk
Unlock market potential advantage
Improve return on investment for repurposed drugs
Explore out-licensing options

This meeting aims to help pharma, biotech and academics stay ahead of the curve in their repurposing endeavors during a period exploding with new technologies. Join cutting-edge discussions with the like of AstraZeneca, BenevolentAI, and Healx, to solve ongoing technical challenges surrounding AI tools in repurposing, understand the delicate risk-reward balance in potential repurposing opportunities and explore lessons learned from AI applications in repurposing during Covid-19.
Featuring 2 days of jam-packed content, this digital summit will provide you with all the information you need to begin implementing AI tools into repurposing projects within your organization. What’s more, our digital platform allows you to take part in live Q&A with the presenters, take a tour of the virtual exhibition, and even join online rooms where you can join targeted interactive discussion groups!
To know more about AI Driven Drug Repositioning and Repurposing Summit please click here.

Anti-Infectives Drug Development – Digital Summit
2021-04-20 - 2021-04-22 | Digital Event, EDT
Infectious diseases are one of the largest threats to global public health. The focus on the threat has never been greater, with the COVID-19 pandemic demonstrating the critical need for a more proactive approach within governments, biopharma, and investment communities to overcome the pressing issues in anti-infective drug development to combat antimicrobial resistance.
With some now considering the field as the new ‘Wall Street darling’, especially given the $1 billion launch of the AMR action fund, the Digital Anti-Infectives Drug Development Summit has arrived as the most comprehensive and industry-dedicated forum that addresses the biggest challenges in the development and commercialization of anti-infective drugs.

Bringing together 60+ senior leaders from large pharma, innovative biotech, academia and investment companies, join us this April to discuss data-driven and solution-based approaches that focus on developing high value clinical candidates, novel modalities and effective strategies, that address market sustainability and aim for superiority.
What you can expect:

Reimagine anti-infective drug development to ensure economic sustainability, with insight from Merck, CARB-X & AlloVir

Explore the non-traditional approaches employed to combat multi-drug resistance, with insight from Locus Biosciences, Peptilogics & SciBac

Advance the clinical superiority of anti-infectives to drive commercial success, with insight from ContraFect & Summit Therapeutics

Target the unmet medical need to ensure drug development pipeline success, with insight from BioVersys, Entasis Therapeutics & Spero Therapeutics

Discover superior novel strategies to combat anti-microbial resistance, with insight from Techulon, MicuRX & Princeton University

To know more about Anti-Infectives Drug Development please click here.

4th Annual MarketsandMarkets Real-World Data, Life Sciences Analytics and Market Access Virtual Conference (Time Zone - EST)
2021-04-22 - 2021-04-23 | Virtual Event
MarketsandMarkets is proud to announce the 4th Annual MarketsandMarkets Real-World Data, Life Sciences Analytics and Market Access Virtual Conference to be held on 22- 23 April, 2021.
While the 3rd annual virtual conference had discussions on how the insights derived from real world data, as well as acknowledgment of the effect the insights can have on improving decision making and patient consideration both internally and by regulators, doctors, and payers, the 4th Annual conference will focus on discussion about the application of RWD/RWE across the life cycle. The event will discuss Impact of COVID-19 on the real-world generation and making sense of the Electronic Health Records data for COVID-19.
Our aim for the 4th Annual Virtual Conference is to unite all stakeholders in a virtual room to learn how to overcome the challenges caused due to the pandemic, efficiently and effectively generating RWE for stakeholders including payers, patients and physicians.
Event Website https://events.marketsandmarkets.com/4th-edition-marketsandmarkets-real-world-data-life-sciences-analytics-and-market-access-virtual-conference-uk-eu/
Registration link: https://events.marketsandmarkets.com/4th-edition-marketsandmarkets-real-world-data-life-sciences-analytics-and-market-access-virtual-conference-uk-eu/register

Pre-Filled Syringes East Coast 2021
2021-04-26 - 2021-04-27 | Virtual conference: Online access only
SMi are proud to announce the 8th Pre-filled Syringes East Coast virtual conference taking place on 26th and 27th April 2021.
The global pre-filled syringes market was valued at $4.9 billion in 2018 and with the rapid growth of the industry, is expected to exceed $9.7 billion by 2025. With that in mind, this event will bring together specialists within the industry to provide an exclusive insight into the sphere of regulation, new digital technology trends, human studies and innovative design and delivery systems within the prefilled syringe industry.
This comprehensive overview will help attendees understand the changing global market and the challenges faced within the industry. The upcoming conference will cover key topics driving the industry including advancing development for drug delivery devices, regulatory updates including the FDA draft guidance on bridging studies, connectivity and digital health for combination products and compatibility for drug delivery systems.
This two-day agenda offers you peer-to-peer networking with Global Product Managers, Senior PFS Engineers, Device Testing Managers, Heads of Late-Stage PFS Development and many more.
We look forward to welcoming you to the conference in April 2021.

Who should attend:

Drug-delivery developers
Medical Device Engineers
Primary Packaging material designers
Secondary packagers
Smart device developers
Training device developers
Device-safety solution providers
Drug developers

To register or for more information visit: www.pfsamericas.com/pjwl
Benefit of attending:
Pre-Filled Syringes East Coast will explore the latest industry updates on pre-filled syringes exploring considerations for platforms and integrated development. Gain insights into how the industry has overcome challenges of the pandemic with case studies on human factors studies and the acceleration towards connectivity for delivery devices. Hear from leading industry and regulatory experts on life cycle management, guidance on bridging studies and biocompatibility considerations.
The SMi Virtual Conference Platform will deliver the following benefits:

Live and On Demand speaker content: Get access to the latest strategies and case studies from your marketplace online!
Network with all the event attendees: Connect, see who’s attending, chat and share contact details with all online delegates, speakers and sponsors
Exhibit a Virtual Booth: You can pack your customized booth full of documents, videos and even show who is manning the booth during the event and hosting meetings
Host & Join Meetings & Socials: Join preferred speaking sessions, host you own meetings and even a virtual Networking social, with in built Zoom functionality

Additional Contact Info:
T: +44 (0)20 7827 6088
E: hsidhu@smi-online.co.uk
Twitter: @SMiPharm #Smipfsusa
LinkedIn: follow our company page – search ‘SMi Pharma’

Strategic Operational Excellence in Life Sciences
2021-04-26 - 2021-04-28 | Exclusive Virtual Conference
Strategic Operational Excellence in Life Sciences is a brand new forum, designed for and by strategic operations and operational excellence leaders in the Life Sciences, with a vision to create a holistic, enterprise-wide dialogue around business excellence innovation, to ultimately redefine operational excellence as a competitive advantage for the modern scientific organization.
It will shine a light on the boldest operational excellence leaders from the most admired biopharma and medical devices businesses, sharing their stories of process excellence innovation, nurturing cultures of continuous improvement and re-examining supply chain operations during and beyond Covid-19.
To know more about Strategic Operational Excellence in Life Sciences please click here.

Interstitial Lung Disease Drug Development Summit
2021-04-27 - 2021-04-29 | Virtual Conference
Network with over 50 other industry pioneers including Ionis Pharmaceuticals, Genentech, Vicore and AnaMar to hear first-hand how the latest scientific research is innovating and upgrading ILD therapeutics at this trailblazing new meeting.

The 1st Interstitial Lung Disease Drug Development Summit is a ground-breaking new conference dedicated to helping you drive forward the development of effective therapies for chronic fibrosing ILDs and achieve success in anti-fibrotic drug development beyond IPF.
Visit our website to download our event guide.

3rd Neuroimmunology Drug Development Summit
2021-04-27 - 2021-04-29 | Virtual Event
As diverse programs are advancing towards the clinic, there is a dire need to tackle the many translational challenges neuro-immunologists are facing to develop clinically effective neuroimmunology targeted therapeutics.

Building on the success of last year’s meeting, the 3rd Neuroimmunology Drug Development Summit will uncover how leading companies in this emerging field are discovering immune-modulating targets and deploying immuno-neurology across clinical case studies. As we gather the best minds in this infant field we will put a spotlight on the latest key learnings across microglia, astrocytes, STING, TREM2 and more to help pave the way to translating key technological and mechanistic insights towards the clinic.
Join this intimate, industry led forum to not only learn from those pioneering the field, but to network and build meaningful partnerships with 80+ neuroimmunology drug development experts.
To find out more and view the 2021 speaker line-up, download the 2021 event guide.

Mitochondria-Targeted Drug Development Digital Summit
2021-04-27 - 2021-04-29 | Virtual Event
The Mitochondria-Targeted Drug Development Digital Summit is the only industry-led meeting focused on end-to-end mitochondria-targeting. Explore success stories from leading experts overcoming common challenges whilst exploring what’s next to help you accelerate your pipeline into the clinic.
With 20+ hours of content, 2 interactive workshops and over 5 hours of networking with key industry leaders from Larimar Therapeutics, Minovia Therapeutics, Mitokinin and many more, this comprehensive forum will completely focus on mitochondria-targeting drug development and the current challenges and opportunities in the field.

Make this your 2021 must-attend meeting and network with 80+ senior CSOs, CEOs, research scientists, academics and investors committed to targeting mitochondria to tackle challenges with Mitochondrial & Age-related Diseases.
In this focused summit, you’ll learn from the field’s pioneers who’ll be sharing their experience in:

Exploring the role of mitochondrial dysfunction in age-related diseases & rare genetic mitochondrial diseases
Examining early discovery and research findings
Evaluating preclinical drug development and studies
Discovering the patient perspective to aid mitochondria-targeted drug development
Assessing clinical development and showcasing current trials
Lessons learned from clinical trial design and how design can be improved to mitigate common challenges
Realizing the use of gene therapy, editing technology and innovation

To know more about Mitochondria-Targeted Drug Development Digital Summit please click here.

SMi’s 4th Annual Pharmaceutical Microbiology East Coast Conference
2021-04-28 - 2021-04-29 | Online Access Only
Sponsor: Microcoat
Chaired by Lynne Ensor, Vice President, RCS Head of Global Compliance, Parexel
Exploring Agile Contamination Control Strategy
Biologic products require diligent microbial control because of their complex and sometimes growth-promoting manufacturing processes, and high-risk patient populations. The increase in complexity of pharmaceutical products, rise in development of biologics and increasingly stringent regulations for biologics are some of the factors that are driving the growth of the pharmaceutical microbiology market for biopharmaceutical products.

SMi Group invite all microbiologists to join the virtual conference to discuss Contamination Control Strategies, Effective Environmental Monitoring, and the newest schools of thought in personnel operation. Leaders in regulation and compliance will provide expert viewpoints on how to implement and interpret the regulation, in addition, Annex 1 will be assessed and debated.
The industrial microbiology market is made up of equipment and systems. The equipment comprises the filtration pumps & systems, microbial detection systems, air monitoring systems, incubators & culture apparatus, etc. This equipment is used in series of microbiological tests by the industry, where they play a vital role as they provide the ease in the testing procedure. In industrial microbiology test types, microbial tests are carried out to study the total viable count of the specific organism present in a solution.
The Microbiological industry continues to swell and is set to reach a Record CAGR of 7.1% Rise in Growth by 2024. The Global Clinical Microbiology Market is expected to reach USD 4.95 billion by 2023.
Event Hashtag: #SMiPharmaMicroEC
Highlights for 2021:

EXPLORE the latest advancements in robust risk-based disinfection strategies for effective cleaning and microbe elimination
INVESTIGATE the extensive and complex regulatory landscape alongside the regulators
DELVE into recent case studies delivered by experts in microbial monitoring and contamination control programs
ATTAIN expert tuition at the post-conference workshops in new quality risk management tools for contamination control and the latest revisions in the USP
VIRTUAL CONFERENCE benefits include: virtual exhibition booths packed with information, networking features to discuss and share contact details with other attendees, and virtual meetings and networking socials

2 Interactive Pre-Conference Workshops on April 27, 2021
Workshop A: USP Microbiology 2021 – Keeping Up with Standards
Led by: Donald Singer, Microbiology Expert Committee Chair, US Pharmacopoeia
Workshop B: Quality Risk Management Tools for Contamination Control
Led by: Cheryl Essex, Head of Microbiological Control for Biologics, Sanofi and Jon Williams, Global Proactive Risk Manager, Sanofi
View the full agenda: www.microbiologyeastcoast.com
WHO SHOULD ATTEND?
Senior Microbiologist, Lead Scientist, Laboratory Manager, QA Specialist, Drug Substance External Manufacturer, QC Scientists, Heads of Quality, Business Development Manager, Pharmaceutical Microbiology Consultant, Higher Pharmacopoeia Scientist, Analytical Standards Specialist

Triple Negative Breast Cancer Drug Development Digital Summit
2021-04-28 - 2021-04-29 | Virtual/Online
Improving the Safety, Efficacy & Predictability of Monotherapy & Combinatorial Therapies to Fast-track the Discovery & Development of TNBC Treatments to Reach Patients in Need
This is the primary industry platform specifically dedicated to providing you insight into the latest developments of safe and efficacious blockbuster therapies to treat triple negative breast cancer.
Breast cancer (BC) is the most common solid tumor in women, with the triple negative subtype associated with poorer overall survival and a higher probability of cancer recurrence.
Given the large unmet clinical need in this oncology indication and aligned with recent clinical trial progress, the Triple Negative Breast Cancer (TNBC) Drug Development Digital Summit has been created to provide insight into industry- and academic-led clinical programs developing immune checkpoint, DDR inhibitor, ADC and other novel agents.
This is the industry’s definitive conference specifically dedicated to advancing the development of both monotherapy and combinatorial therapies to improve the current standard of care for patients with TNBC.
Join leading experts from CytoDyn, Zenith Epigenetics, Oncorus, University of Pittsburgh and more who are identifying specific molecular targets, such as immune checkpoint modulators, intra-nuclear targets, intracellular targets, and cell surface targets, to limit the progression and metastasis of this invasive tumor and improve patient outcomes.
Whether you are developing a TROP2-ADC, a PARP inhibitor, a viral immunotherapy or a cancer vaccine for treating TNBC, this dedicated digital meeting is your opportunity to discuss novel, cutting edge targeted therapies in TNBC and get a full picture of the clinical landscape.
To know more about Triple Negative Breast Cancer Drug Development Digital Summit please click here.

The 4th Global NASH Congress
2021-04-28 - 2021-04-29 | Online & on-demand
The Global NASH Congress programme creates a collaborative environment in which you can create enduring relationships across the full range of disciplines engaged in NASH research & drug discovery and development.

Learn how to integrate NAFLD Screening into secondary and tertiary care
Discover the regulatory pathways for approval of biomarkers in NAFLD patients
Review the current and potential biomarkers for staging
Investigate if targeting fructose metabolism offers a NAFLD/NASH therapy
Hear how belapectin, a galectin-3 (Gal-3) inhibitor, is in development for the prevention of oesophagal varices in patients with NASH cirrhosis
Explore the Epidemiology of NAFLD

To know more about The 4th Global NASH Congress please click here.

Multi-Functional Cell Therapies Summit
2021-05-04 - 2021-05-06 | EST | Digital
Advance Cutting-Edge Research and Development with Next-Generation Cell Therapies, to Deliver Best-in-Class Products to Patients in Need
Cell therapies hold life-saving potential for patients, and the race is on to develop best-in-class, living, ‘thinking’ drugs. Relapse rates and barriers to solid tumor efficacy mean the cell therapy industry must innovate, now more than ever.
The inaugural Multi-Functional Cell Therapies Summit gathers the avantgarde to discuss strategies to weaponize cell therapies with antigenic, engineered and combination approaches to create sophisticated, multi-functional systems.
For more details about the program, speaker faculty or pricing and discounts, download the brochure.

Chronic Hepatitis B Drug Development Summit
2021-05-05 - 2021-05-06 | Virtual Summit
The first ever meeting purpose-built for discussing the advancement of curative therapies for chronic HBV infection.
Featuring an all-star speaker faculty from across industry, NGOs and academia, all dedicated to finding a curative therapy for Chronic HBV infection. This is a unique opportunity to review the latest clinical investigations with novel and classic therapeutics including RNAi and immuno-therapies.

Here is just a snapshot of some of the speakers who are joining us:
Yuchun Nie, Senior scientist, Aligos Therapeutics
Gaston Picchio, Chief Development Officer, Arbutus Biopharma
William Delaney, Chief Scientific Officer, Virology, Assembly Biosciences (USA)
Stephane Daffis, Scientist II, Gilead Sciences
Patricia Mendez, Vice President – Clinical Development, Immunocore Ltd
Andrew Vaillant, Chief Scientific Officer, Replicor Inc.
Tom Evans, Chief Scientific Officer, Vaccitech
David Anderson, Chief Scientific Officer, VBI Vaccines Inc.
Don’t miss out on this opportunity to benchmark yourself against the competition, get a comprehensive update on how the field stands and network with peers from across the field at the inaugural Chronic Hepatitis B Drug Development Summit. Find out more >> https://ter.li/haruyt

SMi’s 5th Annual Highly Potent Active Pharmaceutical Ingredients Conference (HPAPi)
2021-05-10 - 2021-05-11 | Online Access Only
Innovations in HPAPI Containment & Facility Design for Successful Manufacturing
Sponsored by: Catalent Pharma Solutions and FPS Food and Pharma Systems
Chaired by: Justin Mason-Home, Director, HPAPI Project Services Limited
SMi is delighted to announce its 5th Annual Highly Potent Active Pharmaceutical Ingredients Virtual Conference on 10th and 11th May 2021.

Highly Potent Active Pharmaceutical Ingredients (HPAPIs) play an increasing central role in the fight against many diseases. There is an increasing need to protect workers who handle HPAPIs along the life cycle of the drug product manufacturing, from synthesis of the pharmaceutical active ingredient to distribution of the finished medicinal product. This year’s event will focus on 4 key themes: best practices for toxicological assessment, innovations in containment and facility design, advances in the use of robotics and automation in manufacturing processes, and environmental considerations. Key case studies will be highlighted throughout these themes, revealing the key challenges for current HPAPI manufacture, and insights into the latest technological and regulatory advances in this increasingly potent environment.
Attend the conference and join our networking platform for industry professionals to provide you with the expertise to overcome the challenges of the HPAPi industry.
Key Speakers for HPAPi include:

Ester Lovsin-Barle, Head of Product Stewardship and Health, Takeda
Richard Denk, Senior Consultant Aseptic Processing & Containment, SKAN AG
Raphael Nudelman, Director of Chemical & Computational Toxicology, Teva Pharmaceutical
Olindo Lazzaro, Director Global EHS, AbbVie
Fred Ohsiek, Senior Specialist, Cleaning Validation, Novo Nordisk
Florian Grundmann, MSAT Team Lead, Cleaning Validation, Roche
Ildiko Ziegler, QA Manager, Vanessa Research
Jack Brown, Senior Research Fellow, formerly Boehringer Ingelheim
Reinhold Maeck, Head of Corp EHS Regulatory Intelligence, Boehringer Ingelheim

Doreen Parrish, Head of Corporate Audit, Global EHS, Takeda
Key Reasons to Attend HPAPi:

Explore best practices in hazard assessment and occupational toxicology
understand strategic considerations for planning pilot plants and scaling up manufacturing capabilities for high potency compounds
discover potential for automation and robotics in pharmaceutical manufacturing and technologies for protecting operators from hazardous substances
discuss the opportunities for effective CDMO relationships and explore methods for strengthening those partnerships
Delve into the expanding ADC market within and beyond oncology
Virtual conference benefits include virtual exhibition booths packed with information, networking features to chat and share contact details with attendees

View the full agenda: www.highlypotentapi.com/PJwl

SMi’s 21st Annual Pain Therapeutics Conference
2021-05-10 - 2021-05-11 | Virtual Conference – Online Access Only
Sponsored by: MD Biosciences and Transpharmation
Chaired by Michael Scherz, Founder & CEO, Metys Pharma and Naheed Mirza, Early Development Pain & CNS Specialist
Explore Cutting Edge Drug Discovery Science and Key Clinical-Stage Pain Therapies in the Pipeline
SMi’s 21st Pain Therapeutics Conference will focus on looking into research within pain therapeutics. In particular, the long-term (HEAL) initiative will be discussed and its role in advancing research to reduce the risks of opioid use and misuse and improve pain management, thereby reducing reliance on opioids and the national opioid public health crisis. Talks will also address the importance of sex, gender and race in pain research, including biomarkers, molecular targets, clinical and experimental models of pain.

The conference also address cutting edge drug discovery science, preclinical development trends, analysis of key clinical-stage pain therapies, with a focus on highlighting the importance of biomarker discovery and its contribution to early stage studies on pain. This will be topped off with a panel debate on rethinking pain clinical trials during the COVID-19 pandemic. And further look into treating painful osteoarthritis of the knee with a novel anti NGF, anti-TNFα bispecific fusion protein as well as therapeutic novelties signifying a paradigm shift in migraine prevention. Additionally, the conference will explore Botulinum neurotoxin, Sigma 1 proteins and AP-325 as novel treatment for neuropathic pain as well as the high unmet medical need to develop a novel non-drowsy skeletal muscle relaxant and explore pain genetics in rare diseases as well as the Opioid Crisis and the future of addiction and Pain Therapeutics.
Join Europe’s leading Pain Therapeutics Virtual Conference in May 2021 to explore cutting edge drug discovery science and key clinical-stage pain therapies in the pipeline, bringing together leading pharmaceutical companies and to discuss solutions for the challenges of clinical trial design and conduct.
#SMiPain
Key Reasons to Attend the Conference:

Discover which innovative new therapies are driving clinical development including case studies from Novaramed and Vapogenix
Examine the best strategies to generate more funding in pain research clinical trials to eliminate the issue of underfunding
Explore how COVID-19 has changed the experience of clinical trials and presented an opportunity to reform the way we approach data verification, data analysis and data collection
Understand the role of biomarkers in evaluating target engagement of new drugs and predicting analgesic efficacy
Virtual Conference Benefits include virtual exhibition booths packed with information, networking features to chat and share contact details with other attendees, and virtual meetings and networking socials.

WHO SHOULD ATTEND
Chief Executive Officer, Chief Scientific Officers, Chief Medical Officers, Managing Directors, CEO, Head of Department, Principal Research Scientists, Clinical lead, Clinical Operations in the following fields:

Pain and Migraine
Inflammation
Chronic Pain
Neuropathic Pain
Analgesic pre-clinical development
Anaesthesia and Pain Management
CNS clinical trials
Ion Channel Pharmacology
Pharmacology Intelligence
Translational science
Drug development
Exploratory development

View the full agenda: http://www.pain-therapeutics.co.uk/PJwl

Manufacturing Assets and Facility Management in Pharma Summit 2021
2021-05-11 - 2021-05-13 | Virtual Conference
Manufacturing Assets and Facility Management in Pharma Summit returns in 2021. Taking place virtually this May 11-13, a must attend event to help modernize your facility and revitalize your asset management strategies. Join this cutting-edge discussion and network with engineering, maintenance and manufacturing facilities leaders.
To know more about Manufacturing Assets and Facility Management in Pharma Summit 2021 please click here.

Injectable Drug Delivery 2021
2021-05-12 - 2021-05-13 | St. James’ Court, 54 Buckingham Gate, Westminster, London, SW1E 6AF, United Kingdom
Assessing the innovations in formulations and devices for enhanced injectable delivery
SMi Group is pleased to announce the third annual Injectable Drug Delivery conference, which will be held in London on the 12th and 13th May 2021.
Part of Europe’s leading Injectable conference series, Injectable Drug Delivery will assess innovations in drug product formulation and biologics, innovations in device design, quality management and connectivity for enhanced subcutaneous delivery.

With rapid developments in the parenteral space, the injectable drug delivery market is set to reach USD 902.3 billion by 2027, with an increased focus on patient centricity during DDC development and innovations in device development, including new therapeutic applications such as the delivery of siRNA. This year’s event will focus on advances in drug product formulation and innovations of device design and development to aid delivery.
Furthermore, the conference will assess the evolving regulatory environment of injectable drug delivery with industry and regulatory representatives presenting updates on current guidelines.
The two-day agenda also offers peer-to-peer networking with Global Product Managers, Device Testing Managers, Senior Device Engineers, Heads of Device Development, Heads of Formulation and Drug Process Development, and many more.
The benefits of attending:
This conference offers a chance to learn about innovative injectable drug delivery systems with industrial insights on the following:

DELVE into the latest work in complex formulation for subcutaneous delivery
BENCHMARK against leading pharma companies working to enhance device design and development
UNDERSTAND the regulatory environment of the injectables space from leading regulatory and industry advisors
ENGAGE in industry case studies on design controls, human factors and parenteral formulation
EXPLORE advances in connectivity and human factors key learnings in two pre-conference workshops

Who should attend:
Executives, Directors, VPs, Heads, Principals, Managers, Scientists, Researchers of:

Autoinjectors
Wearables
Device Engineering
Human Factors
CMC
Injectables
Sterile Manufacturing
Packaging
Regulatory Affairs

Featured Speakers:

Alexander Zuern, Device testing manager, Novartis International AG
Andrew Warrington, Project Leader & Patient Advocate, Novartis
Benjamin Werner, Scientist, Boehringer Ingelheim Pharma GmbH & Co. KG
Bjorg K Hunter, Regulatory Manager, Devices, GSK
Blake Green, Senior Manager Regulatory Affairs, Amgen
Camille Dagallier, Formulation and Drug Process Development Senior Scientist, Sanofi
Christopher Muenzer, Senior Device Technology Manager, Novartis
Joel Richard, Head of Technical & Pharmaceutical Operations, MedinCell
Mark Palmer, Scientific Leader, Biopharm Device Engineering, GSK
Rebecca Moses, Director, Core Human Factors Inc.
Rupal Nguyen, Principal Engineer, Allergan
Stefania Ragone, Pharmaceutical Assessor, Medicines & Healthcare Products Regulatory Agency (MHRA)
Tina Arien, Principal Scientist, Janssen Pharmaceutica
Vikas Jaitely, Director, Global Regulatory Affairs Transitional Medicine and Devices, Merck

LinkedIn: @SMi Pharma
Twitter: @SMiPharm #SMiInjectables
